Prognostic Impact of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia Treated With Nilotinib or Dasatinib

BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome 9. METHODS: A st...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer
Päätekijät: Quintás-Cardama, Alfonso, Kantarjian, Hagop, Shan, Jianqin, Jabbour, Elias, Abruzzo, Lynne V., Verstovsek, Srdan, Garcia-Manero, Guillermo, O'Brien, Susan, Cortes, Jorge
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4324753/
https://ncbi.nlm.nih.gov/pubmed/21523765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26147
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia